See more : Auroch Minerals Limited (AOU.AX) Income Statement Analysis – Financial Results
Complete financial analysis of AP Biosciences Inc (6945.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AP Biosciences Inc, a leading company in the Biotechnology industry within the Healthcare sector.
- Zad Holding Company Q.P.S.C. (ZHCD.QA) Income Statement Analysis – Financial Results
- LeMaitre Vascular, Inc. (LMAT) Income Statement Analysis – Financial Results
- Orea Mining Corp. (OREA.TO) Income Statement Analysis – Financial Results
- Nykredit Invest Globale Fokusaktier KL (NYIGLA.CO) Income Statement Analysis – Financial Results
- City View Green Holdings Inc. (CVGRF) Income Statement Analysis – Financial Results
AP Biosciences Inc (6945.TWO)
About AP Biosciences Inc
AP Biosciences Inc, a clinical-stage biopharmaceutical company, researches and develops bispecific antibody drugs for unmet medical needs. It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinomas; AP402, which is in in the pre-clinical research phase for breast cancer patients; and AP601 that is in pre-clinical research phase for treating lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors. The company was founded in 2013 and is based in Taipei City, Taiwan.
Metric | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|
Revenue | 32.25M | 0.00 | 6.99M | 137.56K |
Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 32.25M | 0.00 | 6.99M | 137.56K |
Gross Profit Ratio | 100.00% | 0.00% | 100.00% | 100.00% |
Research & Development | 336.60M | 262.68M | 173.81M | 67.36K |
General & Administrative | 43.13M | 34.82M | 19.90M | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 43.13M | 34.82M | 19.90M | 0.00 |
Other Expenses | -347.48M | 6.38M | -1.10M | -3.54K |
Operating Expenses | 32.25M | 297.50M | 193.71M | 92.54K |
Cost & Expenses | 379.73M | 297.50M | 193.71M | 92.54K |
Interest Income | 10.03M | 2.58M | 212.00K | 270.00 |
Interest Expense | 1.20M | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 12.58M | 8.68M | 8.86M | 7.20K |
EBITDA | -325.51M | -290.07M | -177.86M | 52.22K |
EBITDA Ratio | -1,009.25% | 0.00% | -2,543.39% | 37.96% |
Operating Income | -347.48M | -288.54M | -186.72K | -45.02K |
Operating Income Ratio | -1,077.35% | 0.00% | -2.67% | -32.73% |
Total Other Income/Expenses | 8.18M | 8.96M | -187.42M | 86.76K |
Income Before Tax | -339.30M | -288.54M | -187.61M | 41.75K |
Income Before Tax Ratio | -1,051.98% | 0.00% | -2,682.77% | 30.35% |
Income Tax Expense | 0.00 | 0.00 | -186.53M | 90.03K |
Net Income | -339.30M | -288.54M | -187.61M | 41.75K |
Net Income Ratio | -1,051.98% | 0.00% | -2,682.77% | 30.35% |
EPS | -5.24 | -5.48 | -3.89 | 0.01 |
EPS Diluted | -5.24 | -5.48 | -3.89 | 0.01 |
Weighted Avg Shares Out | 64.75M | 52.65M | 48.23M | 6.47M |
Weighted Avg Shares Out (Dil) | 64.75M | 52.65M | 48.23M | 6.47M |
Source: https://incomestatements.info
Category: Stock Reports